Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 62.0 | 66 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 55.0 | 79 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 67.5 | 60 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 65.0 | 81 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 52.0 | 75 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 64.0 | 69 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 70.0 | 53 | |
RA2159 | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 64.5 | 60 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 74.5 | 42 | |
N2645 | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 77.0 | 79 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 64.0 | 55 | |
RA2708 | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 69.5 | 62 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 21.0 | 84 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 25.5 | 70 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 27.0 | 50 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 30.0 | 58 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 22.0 | 66 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 25.0 | 58 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 51.0 | 45 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 45.0 | 73 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 42.0 | 76 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 47.5 | 74 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 52.0 | 69 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 49.0 | 69 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | PDGF-BB | 25.0 | 57 |